Trending...
- $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
- Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
- WebDrafter Highlights How AI Search Is Reshaping Online Visibility
Single ~ CS Genetics, a leading company in next-generation single-cell genomics, has announced the launch of their latest product, the SimpleCell™ 3' Gene Expression kits. This is the company's first commercial offering and is designed to make single-cell transcriptomics more accessible and scalable.
The SimpleCell™ platform utilizes Kinetic Confinement, a revolutionary molecular process, to provide an instrument-free and scalable solution for single-cell genomics. This technology has been in development for several years and is now being released commercially.
Luke Edelman, Founder and Chief Technology Officer at CS Genetics, expressed his excitement about the launch of SimpleCell™. He stated, "After several years of development, we are so excited to be releasing our first SimpleCell™ products commercially. Single cell is a very important and impactful modality for biological measurement, and we feel strongly that a diverse ecosystem of technology platforms – now including Kinetic Confinement and SimpleCell™ – is good for the field and for the cadence of discovery."
More on The PennZone
The SimpleCell™ 3' Gene Expression kits have several key features that make them stand out in the market. These include a single-day cells-to-sequencer workflow using standard lab equipment and pipetting, cost-effectiveness at under $500 per sample regardless of experiment scale or purchase volume, and compatibility with various sample types such as blood/PBMCs, cell lines, disaggregated solid tissues, and more.
CS Genetics will be showcasing details about Kinetic Confinement technology and the SimpleCell™ product line at the 2024 Annual Meeting of the American Society for Human Genetics in Denver. Attendees can visit CS Genetics at booth 402 or join the SimpleCell™ CoLab talk on Wednesday, November 6th at 4:00 PM in Theater 3 to learn more about the future of single-cell genomics.
Early customers of SimpleCell™ have already expressed their satisfaction with the product. Charlly Kao, Principal Scientist at the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, shared, "We've been eagerly waiting for something like SimpleCell™ that can perform single-cell transcriptome profiling in a flexible, instrument-free, and simple-to-use workflow at a more attractive price point."
More on The PennZone
Hákon Hákonarson, Director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine, also commented on the potential impact of SimpleCell™. He said, "Kinetic Confinement and the SimpleCell™ platform are timely new additions to the single cell universe. As a translational research facility with access to a very large number of clinical specimens, we are particularly excited about the opportunities presented by the platform to enable significantly larger-scale single cell studies than has been realistically possible with other tools."
Yuriy Alekseyev, director of the Single Cell and NGS core laboratory at Boston University Chobanian & Avedisian School of Medicine, also praised SimpleCell™ for its affordability and ease-of-use. He stated, "SimpleCell™ checks these boxes well. It's simple to set up, cost-effective, and a welcome addition for users who've been looking for a platform that doesn't require a huge learning curve or large costs for each experiment."
The SimpleCell™ 3' Gene Expression kits are available in 8-sample and 16-sample sizes and can now be ordered for shipment across the U.S., U.K., Europe, and select global regions through CS Genetics' website. To learn more about this innovative product or to place an order, visit www.csgenetics.com.
The SimpleCell™ platform utilizes Kinetic Confinement, a revolutionary molecular process, to provide an instrument-free and scalable solution for single-cell genomics. This technology has been in development for several years and is now being released commercially.
Luke Edelman, Founder and Chief Technology Officer at CS Genetics, expressed his excitement about the launch of SimpleCell™. He stated, "After several years of development, we are so excited to be releasing our first SimpleCell™ products commercially. Single cell is a very important and impactful modality for biological measurement, and we feel strongly that a diverse ecosystem of technology platforms – now including Kinetic Confinement and SimpleCell™ – is good for the field and for the cadence of discovery."
More on The PennZone
- Porter's Day Care Opens Doors to Brighter Futures
- Northeast Airlines and Travel, Inc. Initiates FAA Part 121 Certification for Boeing 737-800 Freighter Cargo Operations
- RevOtter Names Levi Bilbrey CEO, as Company Expands Fractional CMO, RevOps and Web Design Services
- The J Wes Project Announces "The Mystery of Love" Documentary
- Walker's Realty and North Jersey Properties Introduce Extraordinary Luxury Estate for Rent in West Orange, New Jersey
The SimpleCell™ 3' Gene Expression kits have several key features that make them stand out in the market. These include a single-day cells-to-sequencer workflow using standard lab equipment and pipetting, cost-effectiveness at under $500 per sample regardless of experiment scale or purchase volume, and compatibility with various sample types such as blood/PBMCs, cell lines, disaggregated solid tissues, and more.
CS Genetics will be showcasing details about Kinetic Confinement technology and the SimpleCell™ product line at the 2024 Annual Meeting of the American Society for Human Genetics in Denver. Attendees can visit CS Genetics at booth 402 or join the SimpleCell™ CoLab talk on Wednesday, November 6th at 4:00 PM in Theater 3 to learn more about the future of single-cell genomics.
Early customers of SimpleCell™ have already expressed their satisfaction with the product. Charlly Kao, Principal Scientist at the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, shared, "We've been eagerly waiting for something like SimpleCell™ that can perform single-cell transcriptome profiling in a flexible, instrument-free, and simple-to-use workflow at a more attractive price point."
More on The PennZone
- Extreme Heat Strains Home Appliances: Appliance EMT Offers "Summer Rescue" Relief
- Independent West Texas Metal Multi-Instrumentalist & Producer. "MAD CHAD™" Russell Surpasses 1.9 Million Project Interactions Via DFGS Productions
- No Download Needed: Goosechase Adds Browser Play to Every Experience
- HER Patio Productions celebrates one-year Anniversary of "Say Grace"
- Working Musicians Academy Partners with Black Dog Music Partners to Give Musicians Independent, Income-Producing Careers
Hákon Hákonarson, Director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine, also commented on the potential impact of SimpleCell™. He said, "Kinetic Confinement and the SimpleCell™ platform are timely new additions to the single cell universe. As a translational research facility with access to a very large number of clinical specimens, we are particularly excited about the opportunities presented by the platform to enable significantly larger-scale single cell studies than has been realistically possible with other tools."
Yuriy Alekseyev, director of the Single Cell and NGS core laboratory at Boston University Chobanian & Avedisian School of Medicine, also praised SimpleCell™ for its affordability and ease-of-use. He stated, "SimpleCell™ checks these boxes well. It's simple to set up, cost-effective, and a welcome addition for users who've been looking for a platform that doesn't require a huge learning curve or large costs for each experiment."
The SimpleCell™ 3' Gene Expression kits are available in 8-sample and 16-sample sizes and can now be ordered for shipment across the U.S., U.K., Europe, and select global regions through CS Genetics' website. To learn more about this innovative product or to place an order, visit www.csgenetics.com.
0 Comments
Latest on The PennZone
- BTAQ Unveils Easier Photo Upload Capabilities
- K2 Integrity Names Michael Kallabat Global Head of Investigations and Disputes
- WebDrafter Highlights How AI Search Is Reshaping Online Visibility
- Socialhose Eyes Southeast Asia and Rejects the Copy-Paste Expansion Playbook
- $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
- A.M. Logging Returns to Ag Progress Days for Eighth Year
- $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC)
- Lewis County Hydrogen Alliance Launches Phase 1 Work to Turn Forest Residuals into Fuel-Grade Hydrogen and Dispatchable Clean Power
- Next Gen Fibre Selects netElastic vBNG and CGNAT to Fuel Rapid Nationwide Expansion and Eliminate Network Bottlenecks
- Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
- 'Reflections: Enlightening Insights Into the Divine Mystery' — The Latest Book by Philosopher Steven Colborne
- Scott G. Hoy of Hoy Law Earns 11th Consecutive Super Lawyers Selection
- Brother Marcus Unlocks the Vault
- L2 Aviation Selected for U.S. Air Force KC-46 CASPER Multiple Award Contract
- Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH
- Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
- KeysCaribbean Resorts Offer Savings On Summer Vacations Now Through Aug. 31
- Crossroads4Hope Announces The Lipschutz Women's Fund
- AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
- 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!